Earnings call transcript: cBrain returns to growth in H1 2026 as shares jump

cBrain returned to growth in H1 2026 with revenue of DKK 140 million (+6% YoY) and an EBT margin of 26% (above its full-year target of 20%–25%). Full-year 2026 guidance was reaffirmed at 10%–15% revenue growth with EBT margin of 20%–25%, while management expects H2 revenue growth above 15% (base case) and margins in the low 20s. Shares jumped 8.16% to $72.9 (from $67.4), reflecting investor relief after a rare revenue decline in 2025 and confidence that the turnaround is trend-based rather than temporary.

Analysis

The key market mechanism is re-rating durability: this update reduces the probability of a true growth breakage, but it does not yet prove the international expansion case. The domestic business still looks like the core cash engine, so the stock should trade more like a high-margin public-sector software compounder than a one-off turnaround; that supports the multiple, but only if bookings continue to convert in H2. The risk is that investors extrapolate the AI narrative faster than procurement cycles can absorb it.

Second-order, the sovereignty/on-prem angle is more important than the AI branding. In regulated government workflows, the winner is often the vendor that can satisfy data-control and procurement constraints, not the one with the flashiest model; that favors niche platforms over broad cloud suites in specific deals, but it also caps TAM because adoption is fragmented and slow. Microsoft remains the broader structural beneficiary of public-sector digitization, but cBrain’s pitch highlights that some workloads will be bought as compliance infrastructure rather than pure software productivity.

Contrarian view: the move may be partly overdone because the stock already discounted a worse outcome after the prior year’s slump, while the new guidance still implies margin compression in H2 and no clear proof that the U.S./Germany opportunity is scaling. The next catalyst is not sentiment around AI; it is signed orders and whether the pipeline converts into billings before year-end. Falsifiers are simple: if H2 revenue acceleration fails to materialize or margin slips below the guided band, the turnaround thesis loses credibility quickly.

Key Decisions for Investors

• No immediate new long in cBrain on this print; treat the post-earnings pop as a relief rally and wait 4-8 weeks for hard booking evidence or a guidance raise before adding risk.
• Long MSFT on any broad software pullback over the next 1-3 months: cBrain’s sovereign-AI framing reinforces that government AI spend is real, but scale capture still accrues to the largest platform vendor with the deepest distribution.
• Set an alert on cBrain for the next booking update rather than chase the stock; if H2 signed orders do not convert and revenue momentum stalls, fade strength or trim exposure on any further 10-15% rally.